European Heart Journal Advance Access originally published online on March 1, 2006
European Heart Journal 2006 27(7):839-845; doi:10.1093/eurheartj/ehi811
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy
Division of Cardiology, Cardiac Ultrasound Laboratory, and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Yawkey 5984, 55 Fruit Street, Boston, MA 02114, USA
Received 30 November 2005; revised 30 January 2006; accepted 3 February 2006; online publish-ahead-of-print 1 March 2006.
* Corresponding author. Tel: +1 617 726 3443; fax: +1 617 643 1620. E-mail address: jjanuzzi{at}partners.org
Aims The objective of this study was to determine the integrative utility of measuring plasma NT-proBNP levels with echocardiography in the evaluation of dyspnoeic patients.
Methods and results Of 599 emergency department patients enrolled in a clinical study of NT-proBNP at a tertiary-care hospital, 134 (22%) had echocardiographic results available for analysis. Echocardiographic parameters correlating with NT-proBNP levels were determined using multivariable linear-regression analysis. Independent predictors of 1-year mortality were determined using Cox-proportional hazard analysis. Independent relationships were found between NT-proBNP levels and ejection fraction (P=0.012), tissue Doppler early and late mitral annular diastolic velocities (P=0.007 and 0.018), right ventricular (RV) hypokinesis (P=0.006), and tricuspid regurgitation severity (P<0.001) and velocity (P=0.007). An NT-proBNP level <300 pg/mL had a negative predictive value of 91% for significant left ventricular systolic and diastolic dysfunction. Overall 1-year mortality was 20.1% and was independently predicted by NT-proBNP level [HR 8.65, 95% confidence interval (CI) 2.7–27.8, P=0.0003], ejection fraction (HR 0.95, 95% CI 0.91–0.99, P=0.009), RV dilation (HR 2.98, 95% CI 1.05–12.8, P=0.04), and systolic blood pressure (HR 0.97, 95% CI 0.96–0.99, P=0.01).
Conclusion NT-proBNP levels correlate with, and provide important prognostic information beyond, echocardiographic parameters of cardiac structure and function. Routine NT-proBNP testing may thus be useful to triage patients to more timely or deferred echocardiographic evaluation.
Key Words: Natriuretic peptides • Heart failure • Echocardiography
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mogelvang, J. P. Goetze, P. Schnohr, P. Lange, P. Sogaard, J. F. Rehfeld, and J. S. Jensen Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1694 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. M. Corteville, K. Bibbins-Domingo, A. H. B. Wu, S. Ali, N. B. Schiller, and M. A. Whooley N-Terminal Pro-B-Type Natriuretic Peptide as a Diagnostic Test for Ventricular Dysfunction in Patients With Coronary Disease: Data From the Heart and Soul Study Arch Intern Med, March 12, 2007; 167(5): 483 - 489. [Abstract] [Full Text] [PDF]
|
|